Status:
COMPLETED
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Eligibility:
All Genders
18+ years
Brief Summary
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatmen...
Eligibility Criteria
Inclusion
- Patient was aged ≥ 18 years at the time of NSCLC diagnosis.
- Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation.
- Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen:
- Capmatinib
- IO agent in monotherapy (e.g., atezolizumab, pembrolizumab)
- CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed)
- Combination regimen containing IO and CT agents
- Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner.
- Living or deceased at the time of chart abstraction.
Exclusion
- Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time.
- Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period.
- Participation in clinical trials related to treatment for NSCLC at any timepoint.
Key Trial Info
Start Date :
October 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 7 2022
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT06161051
Start Date
October 3 2022
End Date
December 7 2022
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936